openPR Logo
Press release

Rise in Incidence Rate of Venous Thromboembolism is Fueling the Venous Thromboembolism Market

06-28-2017 01:52 PM CET | Health & Medicine

Press release from: Transparency Market Research

Rise in Incidence Rate of Venous Thromboembolism is Fueling

Venous thromboembolism (VTE) is the formation of blood clots inside the blood vessel. These clots restrict blood flow through the circulatory system. It is classified into two type’s deep vein thrombosis and pulmonary embolism. Formation of blood clot in a deep vein (generally in the leg) is called deep vein thrombosis. The formed deep vein thrombosis clot break off and travels to the lungs, called as pulmonary embolism. Pulmonary embolism is a serious complication from deep vein thrombosis. It occurs in almost one-third of patients suffering from deep vein thrombosis. Venous thromboembolism can occur at any age; however, it is common in adults aged 60 and above.

People who are overweight, older, whose blood is thicker than normal or suffer from some other diseases such as autoimmune disorders (rheumatoid arthritis, lupus, etc.) or cancer are at a higher risk of venous thromboembolism. Hospitalization due to major trauma (fractures or immobilization) or surgery increases the risk for venous thromboembolism. Up to 60% of venous thromboembolism cases occur during or after hospitalization. Venous thromboembolism equally affects men and women. Globally, venous thromboembolism is the third most common cardiovascular disease and leading cause of death and disability.

Obtain Report Details @ http://www.transparencymarketresearch.com/venous-thromboembolism-market.html

Venous thromboembolism is a life-threatening medical condition that requires immediate medical treatment. Treatment primarily focuses on breaking the clots and preventing further formation of clots. Treatment includes blood thinning agents such as anticoagulants (such as unfractionated and low molecular weight heparin as well as warfarin), mechanical devices (compression stockings), and thrombolytic therapy (tissue plasminogen activator).

The venous thromboembolism market is expected to expand in the near future, led by the development of novel oral anticoagulants (NOACs) to overcome the limitation of current treatment options and provide improved patient of care. NOACs are classified into direct thrombin inhibitors (argatroban, dabigatran), which inhibit factor IIa (thrombin), and factor Xa inhibitors (rivaroxaban, edoxaban, apixaban). NOACs offer major pharmacological benefits over current vitamin K antagonists (heparin or warfarin). These include rapid onset and offset of action, predictable pharmacokinetics, and less drug interactions, which eliminate the need for regular coagulation monitoring associated with conventional anticoagulant therapy.

Increase in government expenditure, rise in incidence rate of venous thromboembolism, growth in patient awareness about treatment, and high unmet needs of current treatment options are fueling the venous thromboembolism market. However, complex pathophysiology of the disease, high cost of treatment, and side effects associated with it act as key restraints for the venous thromboembolism market.

The venous thromboembolism market can be segmented based on disease type, product type, and geography. In terms of disease type, the venous thromboembolism market can be segregated into deep vein thrombosis and pulmonary embolism. The pulmonary embolism segment is estimated to expand more than the deep vein thrombosis segment, as pulmonary embolism is the third most common cause for hospital related deaths. Based on product type, the venous thromboembolism market can be divided into anticoagulants, medical devices, and others. In anticoagulant segment, NOAC’s market is expected to grow because it eliminates the need for regular coagulation monitoring, overcoming the major limitation of current standard of care.

Make an Enquiry @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25934

In terms of geography, the venous thromboembolism market can be classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the venous thromboembolism market, followed by Europe, due to the higher incidence and prevalence rate than that in Asia Pacific and Middle East & Africa, increase in demand for advance treatment, and rise in geriatric population in the region. Asia Pacific is an emerging market for venous thromboembolism due to the developing healthcare infrastructure and rising government expenditure in the healthcare industry. However, affordability issues, lack of proper treatment, and poor patient education are factors restraining the venous thromboembolism market in such as Middle East & Africa and Latin America.

Major players operating in the venous thromboembolism market include Bristol-Myers Squibb Company, Sanofi S.A., Pfizer, Inc., Daiichi Sankyo Co. Ltd., Johnson & Johnson, AbbVie Inc., Merck & Co., and Astellas Pharma Inc.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rise in Incidence Rate of Venous Thromboembolism is Fueling the Venous Thromboembolism Market here

News-ID: 600201 • Views:

More Releases from Transparency Market Research

Personalized Packaging Market Expected to Reach US$ 56.7 Billion by 2031 with 5.1% CAGR Growth
Personalized Packaging Market Expected to Reach US$ 56.7 Billion by 2031 with 5. …
The global personalized packaging market is experiencing significant growth driven by consumer preferences for unique and customized packaging solutions. Personalized packaging offers brands the opportunity to create memorable and engaging experiences, strengthen brand loyalty, and differentiate their products in competitive markets. Valued at US$ 32.8 billion in 2022, the industry is estimated to grow at a compound annual growth rate (CAGR) of 5.1% from 2023 to 2031, reaching a valuation
Boil-in Bags Market Projected to Reach USD 812.4 Million by 2031 with 6.1% CAGR Growth
Boil-in Bags Market Projected to Reach USD 812.4 Million by 2031 with 6.1% CAGR …
The boil-in bags market is witnessing substantial growth driven by the convenience and efficiency they offer in food preparation and storage. Valued at US$ 424.3 million in 2022, this market is estimated to grow at a robust compound annual growth rate (CAGR) of 6.1% from 2023 to 2031, reaching a valuation of US$ 812.4 million by the end of 2031. Market Overview: Boil-in bags have gained popularity as a convenient solution for
Medical Tubing Packaging Market to Reach USD 11.1 Billion by 2031 with 6.2% CAGR Growth
Medical Tubing Packaging Market to Reach USD 11.1 Billion by 2031 with 6.2% CAGR …
The global medical tubing packaging market serves as a crucial component of the healthcare industry, ensuring the safe and sterile delivery of medical devices and equipment. Valued at US$ 5.7 billion in 2022, this market is expected to witness robust growth, with a projected compound annual growth rate (CAGR) of 6.2% from 2023 to 2031, reaching a valuation of US$ 11.1 billion by the end of 2031. Request Sample Copy of
Fragrance Packaging Market Poised to Surpass USD 4.1 Billion by 2031 with 3.8% CAGR Growth
Fragrance Packaging Market Poised to Surpass USD 4.1 Billion by 2031 with 3.8% C …
The global fragrance packaging market plays a pivotal role in the cosmetics and personal care industry, providing packaging solutions that not only protect fragrances but also serve as an essential component of branding and consumer experience. Valued at US$ 2.8 billion in 2022, the industry is projected to grow at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2031, exceeding US$ 4.1 billion by 2031. Request Sample Copy

All 5 Releases


More Releases for Venous

Venous Skin Ulcer Treatment Market : Lucrative Opportunities
Venous Skin Ulcer Treatment Market: Introduction According to the report, the global venous skin ulcer treatment market was valued at US$ 2.6 Bn in 2019. It is expected to expand at a CAGR of ~5% during the forecast period from 2020 to 2030. Various advanced technologies and treatment options are presently available for venous skin ulcer. The treatment for skin ulcer include different therapies such as compression therapy, advanced wound dressings,
Increasing Prevalence of Venous Thromboembolism to Augment Growth of the Venous …
Venous thromboembolism (VTE) is the formation of blood clots in the bloodstream. Two main types of venous thromboembolism are pulmonary embolism and deep vein thrombosis. The formation of blood clots in a deep vein is called deep vein thrombosis, while the deep vein thrombosis formed breaks the clot and travels to the lungs, known as pulmonary embolism. Sample Copy Of Report @ https://www.coherentmarketinsights.com/insight/request-sample/188 Pulmonary embolism occurs in almost one-third of patients
Venous Thromboembolism Treatment Market Analysis by 2028
Global Venous Thromboembolism Treatment Market: Overview When a blood clot is stuck in a vein is known as venous thromboembolism (VTE), this block the flow of blood to the other parts. A person facing this situation requires immediate medical attention. According to various studies, venous thromboembolism is considered as a third leading cause for vascular diagnosis after heart attack and stroke. There are about 300,000 to 600,000 individuals facing
Venous Syringe Market Size, Share, Development by 2025
Market Research Report Store offers a latest published report on Venous Syringe Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Venous Syringe players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/1021886/global-venous-syringe-market-insights The
Continuous Renal Replacement Therapy (CRRT) Market Report 2018: Segmentation by …
Global Continuous Renal Replacement Therapy (CRRT) market research report provides company profile for Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Medical Co., Ltd., B. Braun Melsungen AG, Bellco, NxStage Medical, Inc., Nipro Corporation, NIKKISO CO., LTD., Toray Medical Company Limited, INFOMED SA and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018
Venous Thromboembolism Market - Global Industry Analysis 2025
According to the International Society on Thrombosis and Haemostasis, Inc., venous thromboembolism (VTE) is a leading cause of death and disability worldwide. Approximately 10 million cases of venous thromboembolism occur annually. VTE refers to the formation of blood clots in vein. If the clot is in deep vein (usually leg), it is called as deep vein thrombosis, while a clot in lungs is termed as pulmonary embolism. Request to download and